drugset / Trial / NCT05802992

The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

NCT05802992

Phase 3 Unknown 30 enrolled Affiliated Hospital of Nantong University
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of investigational drug Colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including Chimeric antigen receptor T-Cell immunotherapy (CART) treatment), and to evaluate the quality of life of the patients.

Timeline

Start
2022-03-30
Primary completion
2024-12-31
Completion
2024-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg
Subject Colchicine Small molecule 1 mg
Background Dexamethasone Small molecule 20 mg Oral
Background Dexamethasone Small molecule 40 mg Oral
Background Lenalidomide Other / unclassified 10 mg
Background Lenalidomide Other / unclassified 25 mg

Indications